Tepmetko

Chemical Nametepotinib
Dosage FormTablet (oral; 225 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyEMD Serono, Inc.
Approval Year2021

Indication

  • Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Last updated on 2/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tepmetko (tepotinib) Prescribing Information2021EMD Serono, Inc. Rockland, MA
Document TitleYearSource
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations.2020The New England Journal of Medicine